Search Results 121-130 of 254 for ❣010라인인증 TG@KORID010 010어플가입인증❣

1. Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer - Mayo Clinic

   Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can ...

2. A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) - Mayo Clinic

   A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) · Overview · Participation eligibility.

3. A Study to Evaluate Effectiveness and Safety of TD-1473 in Ulcerative Colitis - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

4. Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer - Mayo Clinic

   mFOLFIRINOX plus placebo (Arm B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. Both arms will continue treatment until ...

5. A Study to Evaluate the Safety and Effectiveness of APT-1011 to Treat Eosinophilic Esophagitis - Mayo Clinic

   About this study. This is a 2-part randomized, double-blind, placebo-controlled study of APT-1011 in adults and adolescents (≥15 years) with EoE.

6. A Study to Evaluate Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant - Mayo Clinic

   The purpose of this study is test the hypothesis that plasmapheresis plus rituximab prior to or shortly after kidney transplantation can prevent recurrent Focal ...

7. Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma - Mayo Clinic

   PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as ...

8. A Study to Evaluate if Benralizumab Compared to Mepolizumab May be Beneficial in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) - Mayo Clinic

   All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period ...

9. Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma - Mayo Clinic

   The purpose of this study is to determine the safety and effectiveness of bb2121 (Ide-Cel) combinations in subjects with relapsed/refractory multiple myeloma.

10. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis - Mayo Clinic

    The purpose of this study is to assess the safety, effectiveness and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in ...